Merck & Co. 10-Kyear ended 2025-12-31

Executive Summary

Merck’s FY2025 sales grew only modestly despite gains in Keytruda and newer medicines: a 39% decline in Gardasil sales, driven largely by China, offset much of that growth. Acquisitions and pipeline investment are broadening the portfolio, but they increased debt and acquired intangible assets ahead of proven replacement revenue. The immediate test is whether new launches can outrun 2026 pricing and exclusivity losses; the larger investor question is whether they can reduce reliance on Keytruda before expected biosimilar competition in 2028–2029.

Key Financial Highlights

• Revenue mix: Pharmaceutical sales were $58.1B and Animal Health sales were $6.35B, up 8.1%. Keytruda/Keytruda Qlex generated $31.7B—49% of company sales—while Gardasil fell to $5.23B.
• Earnings quality: OCF fell from $21.5B despite higher net income. Higher cash taxes and collaboration, licensing and acquisition payments contributed; inventories and receivables also absorbed $1.18B and $1.09B, respectively.
• Capital return: Dividends totaled $8.18B and repurchases $5.08B. Shares outstanding fell from ≈2.53B to ≈2.47B, a net reduction of ≈53.0M shares.
• Investment and asset exposure: Merck issued $14.0B principal of senior notes during 2025. Goodwill was $21.6B and net acquired intangibles were $26.7B, up from $16.4B; interest expense reached $1.36B.
• Restructuring: FY2025 program charges totaled $2.55B. Management expects the July 2025 program to generate $1.7B in annual savings, substantially by the end of 2027, and intends to reinvest the savings.

Business Developments

Growth shifted toward the U.S., where sales rose 13% to $36.5B; international sales fell 11% to $28.5B. Keytruda growth slowed to 7% from 18% in 2024, but Winrevair rose to $1.44B from $0.419B and Capvaxive reached $0.759B. Gardasil’s decline reflects an unresolved China distributor-inventory overhang: shipments paused in February 2025 and did not resume during the year.

Merck is pursuing new indications, formulations and therapeutic areas rather than relying solely on existing Keytruda infusions. The subcutaneous Keytruda Qlex formulation received U.S. approval in 2025; infant respiratory syncytial virus preventive Enflonsia also launched, and multiple oncology and Winrevair applications face 2026 decisions. October’s Verona acquisition added approved chronic obstructive pulmonary disease treatment Ohtuvayre, which contributed $0.178B after closing. The $9.2B Cidara acquisition closed in January 2026 and added an investigational influenza-prevention candidate; Merck expects a $9.0B Q1 2026 R&D charge. These transactions diversify potential growth drivers, but Cidara’s expected charge and the larger intangible balance put substantial cost ahead of demonstrated returns.

Risk Assessment

• Product concentration and exclusivity: Keytruda represented 49% of sales, and Merck expects biosimilar competition to materially affect it in 2028–2029; replacing that revenue is the defining longer-term challenge.
• Near-term pricing and patent losses: Januvia and Janumet lose U.S. exclusivity in May 2026, Janumet XR in July, and Bridion in July; government-set Januvia pricing already took effect on 1/1/2026.
• China vaccines: Gardasil shipments remain paused amid elevated partner inventory, weaker demand and a competing locally produced vaccine; Merck does not expect a material China sales increase in 2026.
• Pipeline and acquired assets: Clinical, regulatory or commercial setbacks could prevent new products from replacing lost sales and impair the enlarged acquired-intangible balance.
• Funding and cash conversion: Debt carrying value rose to $49.3B while OCF declined; planned manufacturing investment and acquisitions compete with dividends and buybacks for cash.
• Manufacturing and cybersecurity: Complex vaccine and biologic production, third-party dependencies and attacks on interconnected systems could interrupt supply or operations; Merck reported no material cybersecurity effect to date.
• Tax and legal outcomes: The Internal Revenue Service proposed $1.3B of additional transition tax plus $0.260B in penalties, excluding interest; Merck disputes the assessment and also faces product-liability and patent litigation.

Strategic Outlook and Investor Actionables

Management is using launches, acquisitions and reinvested restructuring savings to build revenue beyond Keytruda. Investors should distinguish progress in that portfolio transition from growth that merely postpones the effect of pricing and exclusivity losses.

• Monitor 2026 Januvia-family and Bridion sales against growth in Winrevair, Ohtuvayre and newer launches; the balance will show whether replacement revenue is arriving quickly enough.
• Monitor China Gardasil shipment resumption and international sales; continued inventory blockage would weaken the recovery case.
• Monitor OCF, capital expenditures and debt carrying value after Cidara closes; improved cash conversion without further leverage growth would strengthen the investment case.